Treatment of advanced soft tissue sarcomas with ifosfamide and doxorubicin combination chemotherapy

✍ Scribed by Bari?ta, ?brah??m; Tekuzman, G�lten; Yal�in, ?uay??b; G�ll�, ?brah??m; G�ler, N??l�fer; �zi?ik, Yavuz; Kars, Ay?e; �el??k, ?sma??l; T�rker, Alev; Altunda?, Kadr??; Zeng??n, Nurullah; �ner, Ay?eg�l; Baltali, E?men; Firat, D??n�er

• Publisher: John Wiley and Sons
• Year: 2000
• Tongue: English
• Weight: 101 KB
• Volume: 73
• Category: Article
• ISSN: 0022-4790
• DOI: 10.1002/(sici)1096-9098(200001)73:1<12::aid-jso4>3.0.co;2-k

✦ Synopsis

Our objective was to assess the efficacy of a standard dose ifosfamide and doxorubicin containing regimen in the treatment of advanced soft tissue sarcomas. Forty consecutive patients with a median age of 35.5 years were treated. Ifosfamide was administered at a dose of 2.5 g/m 2 /day as 72-hour continuous infusion with mesna at the same dosage and schedule. Doxorubicin was given at the dose of 60 mg/m 2 /day as 2-hour infusion on day 1. Six patients had a complete response (15%), and 9 (22.5%) had a partial response, fourteen patients (35%) stable disease, and 11 (27.5%) did not respond to chemotherapy. The median duration of response was 13 and 5 months for the complete and partial responders, respectively. The median survival was 37 months. Febrile neutropenia was encountered in 9 cases (22.5%). The present ifosfamide and doxorubicin combination is a moderately effective and well-tolerable regimen in the treatment of advanced soft tissue sarcomas.